Cargando…
Treating the primary in low burden metastatic prostate cancer: Where do we stand?
On the basis of endocrine therapy for patients with low burden metastatic prostate cancer (LBMP), the clinical efficacy and quality of life were compared between prostate-only directed radiotherapy (PODT) and prostate and metastasis radiotherapy (PMRT). From November 2009 to November 2015, total 91...
Autores principales: | Luo, Hua-Chun, Fu, Zhi-Chao, Wang, Xin-Peng, Cai, Lv-Juan, Wang, Feng-Mei, Yin, Qin, Lin, Guishan, Chen, Zhong-Hua, Liao, Shao-Guang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7748322/ https://www.ncbi.nlm.nih.gov/pubmed/33371121 http://dx.doi.org/10.1097/MD.0000000000023715 |
Ejemplares similares
-
Migrant Health Burden: Where Do We Stand?
por: Spagnoli, Laura, et al.
Publicado: (2020) -
Where Do We Stand?
Publicado: (1891) -
Baseline neutrophil-lymphocyte ratio is associated with outcomes in patients with castration-resistant prostate cancer treated with Docetaxel in South China
por: Jiang, Zhi-guo, et al.
Publicado: (2021) -
Utility of Lymphadenectomy in Prostate Cancer: Where Do We Stand?
por: Małkiewicz, Bartosz, et al.
Publicado: (2022) -
Long-term cancer-related fatigue outcomes in patients with locally advanced prostate cancer after intensity-modulated radiotherapy combined with hormonal therapy
por: Luo, Hua-Chun, et al.
Publicado: (2016)